India IDExchange
Sign up
Limited time. Limited Seats.|Foresight ₹85,000 ₹60,000 + 18% GST|12 months of accessGet Foresight

India ID Exchange · Board Seats

Audit Committee Chair Roles in Healthcare and Pharma Industry in India

The India-wide healthcare audit-chair hub—live seats, inventory and R&D judgements, quality assurance, term evidence and fee bands.

The national cohort spans different product, provider and distribution models. A strong candidate states which evidence chain—batch, trial, patient, channel or platform—they can genuinely challenge.

Seats on this page
5
Open now
1
Forecast to open
38
Boards read daily
3,790
Deploy our search agentJump to open seats

Company identity, per-firm fees, deadline and the full brief remain Foresight-only.

01

The seats

What is live now, what the filings suggest is approaching, and what changed on tracked boards.

Open audit committee chair seats—healthcare and pharma across India

The hub reads all recorded locations and preserves each mandate's access boundary. City distribution comes from live seats, not a copied market estimate.

Open now

(1)

Appointment expected within 30 days.

Next 90 days

(4)

Appointment expected in 31–90 days.

How applying works

  1. 01

    Open the seat

    The full brief, committee load and term sit on the seat's own page.

  2. 02

    Apply

    One click from the seat page. No cover letter, no chasing an intermediary.

  3. 03

    Create your profile

    Register if you are new, then add your CV and directorship details once.

  4. 04

    Applied — and matched

    Your profile stays live, so the next matching seat reaches you first.

Other committees in India (3)

Open seats on the same sector’s boards in India, on committees other than the audit committee chair.

What is hidden on the 8 seats above

  • · The company behind each mandate, where it has authorised disclosure
  • · Sitting fees, committee fees and annual retainer — always members-only
  • · The application deadline and the full mandate brief
  • · Direct application, without waiting for a seat to open to free members

Audit Committee Chair Roles in Healthcare and Pharma Industry in India is a narrow, high-competition shape. Foresight members apply the day a seat is posted, up to ten a day; free members wait for the deadline window and a cap of one application a week. On a shortlist of five, that timing is the contest.

Unlock with Foresight

Seats forecast to reach a term boundary

The latest filings record 284 sitting chairs in this cohort. The counts below are term-boundary signals, not announced vacancies; reappointments and early exits can move the date.

22

First term completing

Four to five years served; the board can renew or reopen the skills question.

12

Second term completing

Nine to ten years served; a further consecutive term is unavailable.

4

Past ten years

A succession signal that requires examination, not a claim about any named director.

Board movements in the latest filing period

Exchange filings for Jun 2026 recorded 62 appointments and 54 departures in this page’s measured market. These are filed movements, not inferred vacancies.

MovementBoardDirectorFiled category
AppointedCipla LimitedAchin GuptaExecutive Director
DepartedCipla LimitedUmang VohraExecutive Director
AppointedSun Pharmaceutical Industries LimitedSatyavati BereraNon-Executive - Independent Director
AppointedSun Pharmaceutical Industries LimitedAndreas BuschNon-Executive - Independent Director
AppointedAbbott India LimitedNeeraj JainNon-Executive - Independent Director
AppointedAbbott India LimitedJames WennerNon-Executive - Non Independent Director
AppointedGlaxoSmithkline Pharmaceticuals LimitedRonojit BiswasExecutive Director
AppointedSANOFI INDIA LIMITEDSiraj ChaudhryNon-Executive - Independent Director
AppointedSANOFI INDIA LIMITEDRajani KesariNon-Executive - Independent Director
AppointedNEULAND LABORATORIES LIMITEDMauricio FutranNon-Executive - Non Independent Director
Monitor movements with Foresight
02

The market

The incumbent pool, term pattern, concentration, committee resilience, representation and disclosed pay.

Who holds this seat today

National healthcare audit-chair data supports direct tenure, capacity and composition analysis; sub-sector claims remain out because the filings do not provide them.

284

Sitting chairs

1

Median listed boards

21.4%

Holding 3+ boards

7.5 : 1

Incumbents / boundary

Tenure profile

Under 2 years70 · 24.6%
2 to 5 years137 · 48.2%
5 to 8 years49 · 17.3%
8 to 10 years24 · 8.5%
Over 10 years4 · 1.4%

25

Appointments in 12 months

Filed arrivals only; cessation data is not populated well enough to publish reasons for departure.

8.8%

Observed arrival rate

This is not converted into an implied tenure; that inference conflicts with the measured histogram.

55.6%

Newcomers on one board

Capacity, not an already-large portfolio, is visible in the newly appointed cohort.

Where the live seats are

National pages act as hubs. This distribution uses the location recorded on each live Exchange seat, rather than assuming that every mandate sits in a metro.

Hyderabad2 · 40%
Kolkata1 · 20%
Kochi1 · 20%
Bengaluru1 · 20%

Committee floor and representation

39.3%

At the three-member floor

2

Below three members in the filing

23.9%

Women among recorded chairs, versus 29.3% of members

What the seat pays

Public bands answer the market question without exposing the company-specific figure. The rows below are computed from 234 annual-report records; each denominator is shown.

BenchmarkP25MedianP75P90
Board meeting n=50₹25,000₹50,000₹1 lakh₹1 lakh
Committee meeting n=43₹25,000₹50,000₹1 lakh₹1 lakh
Annual per ID n=58₹1.5 lakh₹4 lakh₹12.8 lakh₹30 lakh
Highest-paid ID n=58₹2 lakh₹5.2 lakh₹18 lakh₹30 lakh

Ranges across companies, not offers. Per-company fees remain gated on each seat’s own detail page.

Open the ID salary benchmark
03

The seat itself

The work behind the title, the sector-specific judgement it requires, and the evidence a nomination committee will test.

What the role actually owns

Reporting

Financial reporting judgement

Challenge estimates, materiality, impairment and disclosure choices before the accounts reach the board.

Controls

Controls and assurance

Connect the internal-control map to internal audit, statutory audit and management remediation without letting gaps fall between owners.

Assurance

Auditor independence

Approve the audit relationship, scrutinise non-audit services and create space for the auditor to speak without management.

Conduct

Whistleblowing and investigation

Protect escalation channels, commission proportionate investigations and keep remediation separate from reputation management.

Why healthcare assurance extends beyond the ledger

Inventory shelf life, channel returns, price controls, research spend, acquisitions and regulatory observations can all change financial reporting. The audit chair must join financial evidence to quality, clinical and distribution systems.

Inventory

Inventory carries expiry and quality risk

Valuation depends on shelf life, batch status, demand, returns and whether stock can legally remain in the channel.

Pipeline

Research creates judgement

Development spend, milestone income, licences and impairment require evidence about technical and commercial probability.

Exposure

Compliance can become a provision

Inspection observations, recalls, price-control disputes and litigation require disciplined probability and disclosure judgements.

Do you qualify for this seat?

A credible chair can trace a financial conclusion back to batch, trial, channel and regulatory evidence while keeping the auditor independent.

  1. 01 · Reporting

    Inventory and revenue depth

    Challenge expiry, returns, rebates, channel loading and cut-off with operational evidence.

  2. 02 · Pipeline

    R&D accounting judgement

    Understand capitalisation, collaboration income, milestones, intangibles and impairment.

  3. 03 · Quality

    Quality-system literacy

    Connect deviations, CAPA, data integrity and recalls to provisions, controls and disclosure.

  4. 04 · Compliance

    Regulatory-exposure judgement

    Separate observation, remediation, probability and material disclosure without minimising uncertainty.

  5. 05 · Conduct

    Investigation governance

    Protect whistleblowing and evidence in sales practice, trial, quality and procurement matters.

  6. 06 · Coverage

    Assurance integration

    Align statutory audit, internal audit and quality assurance without blurring their accountabilities.

04

Doing the job

The dated obligations, the first hundred days, and a practical checklist for the work behind the appointment.

The regulatory year

The healthcare audit calendar replaces the RBI row with CDSCO, quality, clinical and price-control evidence that can affect estimates and disclosure.

First board meeting of the year

Companies Act s.149(7)

Record each independent director's declaration and test conflicts against the current group structure, not last year's chart.

At least once each financial year

Applicable LODR committee regulation

Meet the statutory minimum, but schedule decisions when the evidence is available; an annual formality is not active oversight.

Annual independent-director meeting

LODR Reg. 25(3)

Use the session without management to surface information gaps and agree what must return to the full board.

Before the annual evaluation

LODR Schedule II

Set evaluation criteria before scoring begins and preserve the evidence behind difficult conclusions.

By 30 September

MCA DIR-3 KYC

Confirm every DIN remains active. Administrative lapse can disable a director at the point a committee most needs continuity.

Before quarterly and annual results

LODR Reg. 18/33 and applicable Ind AS

Test inventory, returns, research arrangements, intangibles, provisions and material regulatory matters before recommending results.

After material quality or regulatory events

Drugs and Cosmetics / CDSCO / NDCTR framework

Connect root-cause evidence, recall or remediation scope and regulator correspondence to control, provision and disclosure decisions.

Provision summaries are orientation, not legal advice. Verify the current Act, Listing Regulations and sector direction before relying on an item.

Your first hundred days

The first hundred days should connect audit evidence to the product and patient systems that create the numbers.

  1. Days 1–15

    Meet finance and quality separately

    Hear the statutory auditor, internal auditor and quality head without management filtering the issue map.

  2. Days 15–30

    Trace inventory evidence

    Follow selected batches through status, shelf life, channel returns, valuation and write-off governance.

  3. Days 30–45

    Map pipeline accounting

    Link research stages, licences, milestones and forecast assumptions to recognition and impairment conclusions.

  4. Days 45–60

    Join observation and provision logs

    Compare quality, legal and finance views of probability, exposure and remediation timing.

  5. Days 60–80

    Test sales-practice controls

    Review incentives, samples, discounts, third parties and investigation escalation in a high-risk channel.

  6. Days 80–100

    Retarget assurance

    Put data integrity, quality-to-finance interfaces and unresolved regulatory commitments into the audit plan.

Get the NRC Chair Readiness Checklist

Two pages, free. The appointment tests that decide whether you may chair at all, the four documents to demand before your first meeting, the RBI compensation and fit-and-proper layer that applies to banks, NBFCs and insurers, and the annual cycle most committees miss. Written to be worked through.

No cost. We hold your details only to send board-seat information you asked for, and you can withdraw at any time.

Questions directors actually ask

Does a healthcare audit chair need sector experience?

It is highly valuable because inventory, research, quality and regulatory evidence create judgements unfamiliar to a general reporting role.

Can a quality event affect financial statements?

Yes. It may affect inventory value, provisions, impairment, revenue, going concern or material-event disclosure depending on facts.

What replaces financial-services regulation?

CDSCO, drugs-and-cosmetics, clinical-trial, pharmacovigilance, quality-system and price-control evidence shape the audit agenda.

Must the chair be a chartered accountant?

No statutory monopoly applies, but the chair must demonstrate financial literacy deep enough to lead estimates, controls and auditor challenge.

How are fee ranges calculated?

They are quartiles from annual-report remuneration records, published only when the sample clears the minimum threshold.

Which healthcare audit experience is most transferable nationally?

Evidence-based handling of inventory, quality events, provisions, revenue channels and auditor challenge transfers, while each business model still requires specific diligence.

India ID Exchange Foresight

Deploy our search agent before the shortlist is already written

We read 3,790 boards daily, find the roles that fit your committee, sector and geography, and put the brief, fees and deadline in front of you early.

Start Foresight

Related board-seat resources

Before you apply

What this committee is accountable for, what the seat pays, and how much capacity it will take.